Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
98
resultados
Última actualización
16/10/2026 [06:45:00]
Resultados 50 a 75 de 98
Resumen de: US20260219280A1
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: US20260218299A1
0000 Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Resumen de: US20260217813A1
The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO:1 or SEQ ID NO:24 and a light chain variable region set forth in SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17 or SEQ ID NO:25.
Resumen de: US20260219282A1
0000 Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in the methods of immunoassay.
Resumen de: CN122468979A
The invention discloses application of a reagent for detecting a biomarker in preparation of a product for predicting the activity of ulcerative colitis disease or a product for diagnosing ulcerative colitis disease, and relates to the technical field of inflammatory bowel disease serological markers. The serum CD105 of UC patients is obviously higher than that of a healthy control group, and the CD105 has an extremely high effect of diagnosing ulcerative colitis diseases and can distinguish disease activity from disease relief. Therefore, the invention provides a novel serum marker which is convenient to sample, good in repeatability and capable of objectively reflecting the inflammation load of the colonic mucosa, and more accurate marker selection is expected to be provided for UC disease activity prediction and UC diagnosis.
Resumen de: CN122461392A
The granules are prepared from 11 raw material medicines including codonopsis pilosula, bighead atractylodes rhizome, poria cocos, wintercreeper, sanguisorba officinalis, herba lycopi and the like according to specific parts by weight, mixed auxiliary materials of dextrin and soluble starch (the mass ratio is 2: 1) are supplemented, and the dosage of the auxiliary materials accounts for 20%-30% of the total solid content of extract. The preparation process comprises the following steps: crushing the medicinal materials into coarse powder, adding 12 times of water, decocting twice (1 hour each time), and collecting volatile oil; and filtering the decoction, concentrating to obtain an extract with the relative density of 1.10-1.15 at 60 DEG C, adding auxiliary materials to prepare a soft material, sieving with a 16-mesh sieve, granulating, drying at 60 DEG C or below until the water content is less than or equal to 8.0%, finally dissolving volatile oil with ethanol, spraying into the granules, and uniformly mixing. The critical relative humidity of the granules is 77.35%, the quality detection adopts thin layer chromatography to identify medicinal materials such as bighead atractylodes rhizome and the like, and high performance liquid chromatography is adopted to determine the content of gallic acid (not less than 1.20 mg per 15g). The traditional Chinese medicine composition is scientific in compatibility, clear in process parameters, controllable in quality and suitable for t
Resumen de: CN122444873A
The invention belongs to the technical field of biology, and particularly relates to an anti-TL1A nano antibody and application thereof. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of the nano antibody are respectively shown as SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence of a heavy chain variable region of the nano antibody is shown as SEQ ID NO: 1. According to the invention, the alpaca natural nano-antibody library is utilized, and the phage display technology is combined, so that the high-affinity nano-antibody targeting TL1A is successfully screened. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physical and chemical stability. Based on the TL1A targeting characteristic of the nano antibody, the nano antibody has important application value in accurate diagnosis and targeted therapy of TL1A high expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is especially suitable for developing high-sensitivity in-vitro diagnostic kits and novel biological therapeutic drugs.
Resumen de: WO2025185743A1
Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).
Resumen de: US20260209366A1
This invention describes methods, kits, and compositions for treating Food Protein-Induced Enterocolitis Syndrome (FPIES) and a food-triggered endotype of IBS by modulating the IL-4/IL-13→IL-4Rα axis and/or the OX40-OX40L costimulatory pathway, with patient selection and monitoring guided by blood biomarkers (elevated OX40L on dendritic cells and/or OX40 on lymphocytes, including food antigen-stimulated assays). In case examples, IL-4Rα blockade (e.g., dupilumab) produced rapid, durable clinical remission with successful food reintroduction, accompanied by reduced dendritic-cell OX40L and modulation of circulating CRTH2+ Tc2 cells, whereas OX40L-low, non-food-trigger IBS showed no response—supporting a biomarker-defined responder population. Collectively, this invention demonstrates a precision framework in which IL-4Rα and OX40/OX40L antagonists—alone or in combination—enable diet liberalization and induce tolerance in FPIES and food-triggered IBS.
Resumen de: US20260209333A1
0000 Provided are various embodiments relating to caninized, felinized, or equinized antibodies that bind canine, feline, and/or equine IL23 and/or TNFα, including bispecific antibodies that bind to both IL23 and TNFα. Such antibodies can be used alone or in combination in methods to treat canine, feline, and/or equine subjects with inflammatory conditions, such as inflammatory conditions in canines and felines, such as inflammatory bowel disease (IBD), osteoarthritis, and gastroenteritis.
Resumen de: US20260212495A1
0000 The invention relates to system and methods for predicting and/or diagnosing of IBD from ultrasound images according to one or more of diagnostic signs.
Resumen de: WO2026155051A1
The present invention provides an examination method for identifying a biomarker capable of detecting the remission phase of an inflammatory bowel disease, and assisting in the diagnosis of the inflammatory bowel disease, the monitoring of disease progression, or the determination of therapeutic effect. Focusing attention on myeloid immune cells that play an important role in the pathogenesis of inflammatory bowel disease, the present inventors considered that young myeloid immune cells potentially increase even in the remission phase and may induce transition to the active phase by progression of the disease. The present inventors then proceeded with intensive studies thereon. As a result, the present inventors found that CD11b, CD33, and CD84-positive (CD11b+CD33+CD84+) cells, which are precursor cells of myeloid immune cells, can serve as blood markers for inflammatory bowel disease. Further investigation revealed that Membrane-Spanning 4-Domains A3 (Ms4a3)-positive (Ms4a3+) cells, and Ms4a3 and CD84-positive (Ms4a3+CD84+) cells significantly increase not only in the active phase but also in the remission phase, and are significantly greater in number in the active phase than in the remission phase.
Resumen de: US20260210970A1
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
Resumen de: US20260209867A1
0000 The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.
Resumen de: CN122428031A
The invention discloses an ulcerative colitis diagnostic marker based on BASP1 and S100A11 gene expression quantities and application of the ulcerative colitis diagnostic marker, and belongs to the technical field of biomedical detection. Through a consensus screening strategy integrating Lasso regression and multiple machine learning algorithms, BASP1 and S100A11 genomes are screened out from peripheral blood transcriptome data to cooperate as diagnostic markers of ulcerative colitis. Furthermore, the invention provides a kit for detecting the marker combination, and the kit comprises a specific primer pair SEQ ID NO: 1-4. Experiments prove that the marker combination shows stable diagnosis efficiency in a plurality of independent data sets, the AUC value verified by clinical samples reaches 0.846, the sensitivity is 79.45%, and the specificity is 78.72%. The invention also discloses a correlation mechanism of the marker combination and UC immune microenvironment change through immune cell infiltration analysis and GSEA enrichment analysis. The invention provides a noninvasive, efficient and accurate molecular diagnosis scheme for ulcerative colitis, and has a good clinical transformation prospect.
Resumen de: CN122405811A
The invention discloses an application of a hairy spirillum bacterium serving as an intestinal flora marker in preparation of a product for screening or diagnosing the damage degree of a plateau intestinal barrier. The hairy spirillum bacterium comprises LacnospiraceaeNK4A136 group. The invention further discloses a preparation method of the hairy spirillum bacterium, and the application of the hairy spirillum bacterium to the preparation of the product for screening or diagnosing the damage degree of the plateau intestinal barrier. Research finds that a 16s high-throughput sequencing result in a rat plateau intestinal barrier damage model shows that the abundance of the strain on the genus level is remarkably reduced, and under the condition that other intestinal barrier protection functional base materials are added, the strain shows relatively high atopic property and sensitivity at the same time, the plateau intestinal barrier damage degree can be represented, and the strain has a good application prospect. The intestinal barrier damage indexes are consistent with other intestinal barrier damage indexes; therefore, the marker can be used as a detection marker to be applied to diagnosis or screening of the damage degree of the plateau intestinal barrier and evaluation of the treatment effect.
Resumen de: CN122409882A
The invention provides a screening method of a blood metabolism marker for evaluating rectal cancer prognosis and a metabolism marker composition. The metabolite provided by the invention is used as a marker for predicting rectal cancer prognosis, and has the advantages of non-invasive detection, high sensitivity, high specificity, high throughput analysis capability, low cost and early prediction. The method not only overcomes the invasiveness and limitation of traditional biopsy, but also can provide an important basis for clinicians to adjust treatment strategies by monitoring the change of metabolites in real time. The marker combination disclosed by the invention can accurately predict the curative effect of rectum cancer neoadjuvant therapy, and an innovative and efficient evaluation tool is provided for clinicians.
Resumen de: CN122405817A
The invention relates to the field of biological medicine, in particular to noninvasive excrement TMEM109 gene methylation detection of IBD secondary intraepithelial neoplasia. The invention has the significance that a commercial product and a standardized method for noninvasive monitoring of secondary intraepithelial neoplasia of the inflammatory bowel disease (IBD) by adopting a qMSP/MethyLight method based on fecal sample TMEM109 gene methylation do not exist clinically at present, and huge unsatisfied requirements exist in clinical practice. The enteroscopy frequency in the disease management process of IBD patients can be reduced, the life quality is improved, the medical expenditure is reduced, and early intervention of IBD secondary early cancer is facilitated.
Resumen de: US20260201470A1
0000 Described herein are systems and methods for identifying gene clusters in patients that have Crohn's Disease (CD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: WO2026150017A1
The present invention relates to a method to predict the sensitivity of a subject to emulsifiers. Here, the inventors explored the use of an in vitro microbiota system and metagenome-based bioinformatic modeling to predict CMC sensitivity of a given microbiota. They found that CMC sensitivity associated with a unique metagenomic signature, supporting the notion that emulsifier sensitivity could be predicted from metagenomic data. They next confirmed that microbiotas predicted to be CMC-sensitive conferred CMC sensitivity when transplanted into colitis-prone IL-10-/- germfree mice. This approach validated the ability of an ex vivo approaches to predict CMC-sensitivity, thereby advancing development of microbiota- based personalized nutrition strategies. Thus, the present invention relates to a method to predict the sensitivity of a subject to emulsifiers comprising determining in a sample obtained from the subject the relative abundance of the microbiota-derived DNA markers listed in the Table A.
Resumen de: EP4775989A2
The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt+Th or RORγt+Treg cell levels and treating the subject accordingly.
Resumen de: CN122385867A
The invention provides a biomarker combination model for evaluating endoscopic activity of pediatric Crohn's disease as well as a construction method and application of the biomarker combination model, and belongs to the technical field of biological medicines. According to the biomarker combination model based on the peripheral blood CD8 + CD69 + T cell proportion combined with the C-reactive protein level, the endoscope activity of a patient suffering from the pediatric Crohn disease can be effectively evaluated through simple peripheral blood detection, and the invasiveness, high cost and potential risks of endoscope detection are avoided; the system is especially suitable for pediatric patients needing frequent monitoring. The model has good diagnosis efficiency, can accurately distinguish patients in an endoscope active period from patients in a remission period, makes up for the defect that clinical activity indexes are inconsistent with endoscope activity, provides a simple, convenient and objective non-invasive evaluation tool for treatment decision, curative effect monitoring and long-term follow-up visit of the pediatric Crohn disease, and has a wide application prospect. Important clinical application values and popularization prospects are realized.
Resumen de: WO2018156937A1
Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.
Resumen de: CN122392998A
The invention discloses a data management system and method based on inflammatory bowel disease detection, and relates to the technical field of integrated monitoring of bowel disease detection data, and the method comprises the steps: forming a first detection model based on diagnosis and treatment record data of a medical institution, obtaining self-report data after a patient leaves a hospital, and carrying out the goodness of fit analysis on the self-report data and prediction data, meanwhile, tracking the recurrence data of the inflammatory bowel disease after the patient leaves the hospital; and constructing a second detection model based on the goodness of fit analysis result and inflammatory bowel disease recurrence data after the patient leaves the hospital, grading the medical institutions according to different treatment scores, forming a priority list of each medical institution in the direction of the inflammatory bowel disease, and feeding back the priority list to the administrator port. The objective of the invention is to fundamentally solve the problems of model misalignment and evaluation system disorder caused by deviation of patient off-hospital report data in a current inflammatory bowel disease data acquisition system due to subjective or objective reasons.
Nº publicación: US20260193710A1 09/07/2026
Solicitante:
CEDARS SINAI MEDICAL CENTER [US]
CEDARS-SINAI MEDICAL CENTER
Resumen de: US20260193710A1
Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or postoperative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.
BOPI
Sede Electrónica
